Neurology
-
Randomized Controlled Trial
Memantine induces reversible neurologic impairment in patients with MS.
Cognitive dysfunction is very common in multiple sclerosis (MS) and it severely impairs patients' quality of life. Thus, we explored whether memantine might improve cognitive performance in patients with MS. ⋯ Memantine at a dose of 30 mg/day may induce transient worsening of neurologic symptoms of multiple sclerosis.
-
To examine the impact of delirium on the trajectory of cognitive function in a cohort of patients with Alzheimer disease (AD). ⋯ Delirium can accelerate the trajectory of cognitive decline in patients with Alzheimer disease (AD). The information from this study provides the foundation for future randomized intervention studies to determine whether prevention of delirium might ameliorate or delay cognitive decline in patients with AD.
-
To determine the incidence and mortality rates and predictors of death in myasthenia gravis (MG) and MG crisis in a large US cohort. ⋯ Myasthenia gravis (MG) is still a disease of young women and old men, as reflected by the hospital admission rates. In-hospital mortality of MG is low. Hospital utilization of i.v. immunoglobulin has significantly increased compared to plasma exchange and thymectomy.